Phage Therapy

BiomX Inc. has issued a statement addressing unusual trading activity in its stock, confirming no undisclosed material developments. The company noted recent challenges, including the discontinuation of a Phase 2b trial, cost-cutting measures, a private placement, and a reverse stock split. Despite a broader biotech sector uptick, BiomX’s shares trade below historical averages. Investor sentiment has closely followed clinical and financial news.